The short version: published protocols are shaped by three facts — half-life [the time it takes for half a dose to clear from circulation] determines dosing frequency, receptors adapt to constant stimulation, and some effects need managing over time.
Those facts produce the patterns you see everywhere in the literature: titration ladders in the GLP class [glucagon-like peptide-1 compounds, stepped up one level at a time at fixed intervals], cycling and pulsed timing on the GH [growth hormone] axis, and the near-total dominance of the subcutaneous route [injection into the fat layer under the skin].
Units cause more reported errors than any of it — 1 mg is 1,000 mcg, and IU [the international unit] measures biological activity rather than mass.
- Half-life sets the clock. Native peptides that clear in minutes get frequent or pulsed dosing in study designs; engineered long-acting analogs get weekly schedules. The frequency is chemistry, not preference.
- Titration ladders exist to manage tolerability. GLP-class trials escalate stepwise over weeks because gastrointestinal effects are dose-dependent and fade with time at each step.
- Cycling reflects receptor adaptation. Continuous stimulation can desensitize signaling — a core reason some study designs use on-off structures and pulsed timing.
- Most reported dosing errors are unit errors — nearly always a factor-of-1,000 slip between mg and mcg.
- The primary sources are public. ClinicalTrials.gov publishes registered protocol structures for anyone to read.
Why dosing is structured
Three questions shape every protocol: how fast the molecule clears, what the receptor does under a constant signal, and which effects need managing over time.
Strip away the compound names and nearly every published peptide protocol is answering the same three questions.
How fast does the molecule clear? Peptides span an enormous half-life range. Many native peptides are degraded within minutes of entering circulation, which is why study designs for them use frequent or specifically timed administration.
At the other extreme, modern GLP-class analogs are deliberately engineered to persist for days. Fatty-acid chains that bind albumin and substitutions that resist enzymatic breakdown do that work. That persistence is what makes once-weekly trial dosing possible. When you see a protocol's frequency, you are reading the molecule's clearance in disguise.
What happens to the receptor under constant signal? Receptors exposed to continuous stimulation can downregulate or desensitize — the signal fades even as the input stays constant. This is a central reason some study designs pulse doses, space them, or build in off periods rather than maintaining a constant level.
What effects need managing over time? In the GLP class, gastrointestinal effects — nausea foremost — are dose-dependent and most pronounced when a dose level is new. That single fact explains the most recognizable structure in the modern literature, covered next.
Four repeating patterns
Titration ladders, cycling, meal-relative timing, and the subcutaneous route. Each is a design response to the three questions above, and each has published exceptions.
| pattern | what it looks like in a protocol | the reason behind it |
|---|---|---|
| Titration ladder | Start low, step the dose up at intervals of weeks until reaching a target or maximum-tolerated level. | Dose-dependent GI effects in the GLP class fade with time at each step; the ladder buys that time. |
| Cycling | Defined on-periods and off-periods, or pulsed rather than continuous administration. | Receptor desensitization under constant stimulation; some designs also cycle to isolate effects. |
| Meal-relative timing | GH-axis study designs administer in fasted states — away from meals. | Elevated glucose and insulin blunt growth hormone release in study models; fasted timing preserves the measured response. |
| Subcutaneous route | Injection into subcutaneous tissue dominates protocols across classes. | Digestion destroys peptide chains, so oral bioavailability [the share of an oral dose reaching circulation intact] is generally poor; subcutaneous delivery gives the intact molecule predictable absorption. |
None of these patterns is a rule of nature. They are design responses to the three questions above, and you will find published exceptions to each. But once you can name them, an unfamiliar protocol stops looking like arbitrary numbers and starts reading as a set of decisions with visible reasons.
Units literacy
The dosing errors reported most often are arithmetic, not pharmacology. One milligram is one thousand micrograms, and IU measures activity rather than mass.
Here is the least glamorous and most important section on this page. The dosing errors commonly reported in the literature and in research communities are overwhelmingly not pharmacology errors. They are arithmetic errors, and nearly always the same one: confusing milligrams with micrograms — a factor of 1,000.
| unit | measures | conversion | note |
|---|---|---|---|
| mg — milligram | mass | 1 mg = 1,000 mcg | The unit vials are labeled in. A 5 mg vial holds 5,000 mcg. |
| mcg / µg — microgram | mass | 1,000 mcg = 1 mg | The unit many published protocol amounts are stated in. µg and mcg are the same unit. |
| mL — milliliter | volume | 1 mL = 1,000 µL | Volume of liquid — meaningless for dosing until you know the concentration in it. |
| IU — international unit | biological activity | defined per substance | Not a mass unit. Common in older GH literature. No universal IU-to-mg conversion exists across compounds. |
Two habits keep the literature readable. First, convert everything to one unit before comparing anything. A protocol stated in mcg and a vial labeled in mg are describing the same kind of quantity three decimal places apart.
Second, treat IU as its own category. It measures activity, not mass, so an IU figure from one compound's literature tells you nothing about another compound's.
Mass and volume meet in concentration math — how many mcg sit in each mL of a reconstituted vial. That has its own fundamentals page.
Read a protocol yourself
Registered trial designs are public at ClinicalTrials.gov. Search the generic name, open the arms and interventions section, and read three or four trials rather than one.
You do not need us, or anyone, to summarize the research for you. Registered trial designs are public at ClinicalTrials.gov, and reading one takes minutes once you know where to look.
- Search the compound name — generic name, not brand — and filter to interventional studies.
- Open the study design section. Note the phase, arm count, and whether it is placebo-controlled. Early-phase dose-finding studies are where escalation structures are most explicit.
- Read the arms and interventions. This is where the actual structure lives: dose levels, route, frequency, and any escalation schedule, stated plainly.
- Check duration and endpoints. How long the protocol ran and what it measured tell you what the dosing structure was built to detect.
- Read three or four trials, not one. The structural patterns — ladders, spacing, route — become obvious across a handful of protocols in a way no single study shows.
Published results papers add a further layer — tolerability data by dose level, discontinuation rates, response curves. But the registry alone answers the structural question this page is about: how researchers organized dosing, and why.
What this page is not
None of this is a recommendation, a starting point, or a template. It documents how researchers organized dosing under screening, monitoring, and supervision no reader has.
Everything above describes how published research protocols were structured and why those structures exist. None of it is a recommendation, a starting point, or a template. The gap between a trial protocol and any individual situation is not a detail.
Trial dosing happens under screening, exclusion criteria, monitoring, and medical supervision. Even inside that controlled setting, individual response varies widely. The tolerability tables in any GLP-class paper show the same dose producing very different experiences across participants.
What the literature reports about adverse effects, and how to read that evidence, has its own fundamentals page. Read the protocols as what they are: documentation of research design, not guidance.
FAQ
Why do different sources report such different protocol amounts for the same peptide?
Usually three reasons, and only one of them is pharmacology. First, different study phases ask different questions. Early-phase dose-finding studies span wide ranges by design, because locating the edges is the point of running them.
Second, route and frequency change the relevant amounts. A molecule degraded within minutes of entering circulation gets a different schedule from an engineered analog built to persist for days. The numbers attached to each are not comparable.
Third, unit sloppiness. One source states amounts in milligrams and another in micrograms, which makes two identical protocols look a thousandfold apart.
Convert everything to one unit before comparing anything. Then go to the registered protocol on ClinicalTrials.gov and read the arms and interventions section directly. That section states dose levels, route, frequency, and any escalation schedule plainly.
What does "maximum tolerated dose" mean in a protocol?
It is a formal endpoint in early-phase research, not a label attached to the compound. A trial escalates the dose stepwise until adverse effects cross a threshold the protocol defined in advance. The highest level that stayed inside that threshold is recorded as the maximum tolerated dose.
Three things follow. It is a property of that study's design, because a different acceptability threshold produces a different number.
It is a property of that study's population, which was screened, subject to exclusion criteria, and monitored throughout. And it sits on top of wide individual variation. The tolerability tables in any GLP-class paper show the same dose producing very different experiences across participants.
A maximum tolerated dose describes what one trial found under one set of rules. It is not a ceiling, a target, or a general property of the molecule.
Why do older GH papers use IU while newer ones use mg?
Because growth hormone was historically quantified by biological activity rather than by mass. An international unit measures what a substance does, and it is defined separately for each substance. It was the practical unit before purified standards made mass dosing the norm.
Conversion factors exist for growth hormone specifically, because its standards were formalized. That is the exception rather than the rule.
No universal IU-to-mg conversion exists across compounds, and there cannot be one, because the unit is anchored to activity and activity is substance-specific. Two habits follow from that.
Treat IU as its own category rather than as a mass figure in disguise. And never carry an IU number from one compound's literature into another compound's, however similar the two molecules look on paper. A cross-compound IU comparison is meaningless.
Is community-reported dosing a reliable source?
It is descriptive data about what people report, which is a different thing from evidence. There are no controls.
Nothing verifies that the compound was what the label claimed or that the stated amount was the amount administered. And in a market where unit errors are the most commonly reported mistake of all, that second gap is wide.
What gets posted also selects itself, through survivorship and through the reporting biases of people choosing what is worth sharing.
So we treat community reporting as market information, useful for seeing what is circulating and at what claimed amounts. We do not treat it as a source for structure.
The registered literature is the primary source, and it is public: ClinicalTrials.gov publishes arms, dose levels, escalation schedules, and duration for anyone to read.
Why do GLP-1 trial protocols escalate doses over weeks?
To manage tolerability. In the GLP class, gastrointestinal effects — nausea foremost — are dose-dependent and most pronounced when a dose level is new. They then ease as participants stay at that level.
A titration ladder is the design response. Start at a deliberately low dose, hold, then step up at intervals of weeks until reaching a target or a maximum-tolerated level.
Each step buys the time tolerance needs to develop before the next increase. That single fact explains the most recognizable structure in the modern literature. It also explains why the opening weeks of a protocol combine a sub-therapeutic dose with the roughest adjustment period.
The ladder is not a rule of nature. It is a design response to a dose-dependent effect, and published exceptions to it exist.
Why are most peptides in research dosed by subcutaneous injection?
Because of what digestion does to a peptide. Peptides are chains of amino acids, and the digestive system is built to break exactly those chains apart. So oral bioavailability, the share of an oral dose that reaches circulation intact, is generally poor.
Injection into subcutaneous tissue, the fat layer under the skin, routes around that entirely. It delivers the intact molecule and gives predictable absorption. That is what a protocol needs if a dose level is going to mean anything.
That is why the subcutaneous route dominates published protocols across compound classes. It is also why route sits alongside dose level and frequency as one of the things worth reading off any registered trial.
Like the other patterns on this page, it is a design response rather than a rule, and published exceptions exist.
What is the difference between mg, mcg, and IU?
Milligrams and micrograms are units of mass, and one milligram is one thousand micrograms. Vials are labeled in milligrams — a 5 mg vial holds 5,000 mcg. Many published protocol amounts are stated in micrograms, and the symbols µg and mcg are the same unit.
An international unit is not a mass unit at all. It measures biological activity, it is defined separately for each substance, and no universal IU-to-mg conversion exists across compounds.
Milliliters are a third category again, measuring volume, and a volume means nothing for dosing until you know the concentration in it.
Most dosing errors reported in the literature and in research communities are unit errors rather than pharmacology errors. It is nearly always a factor-of-1,000 slip between mg and mcg. Convert everything to one unit before comparing anything.
Where can I read actual clinical dosing protocols?
At ClinicalTrials.gov, which publishes the registered design of interventional studies for anyone to read. Search the compound's generic name rather than a brand name and filter to interventional studies.
Open the study design section and note the phase, the arm count, and whether the trial is placebo-controlled. Early-phase dose-finding studies are where escalation structures are stated most explicitly.
Then read the arms and interventions section, which is where the actual structure lives: dose levels, route, frequency, and any escalation schedule, set out plainly.
Check duration and endpoints too, because how long a protocol ran and what it measured tell you what the dosing structure was built to detect. Read three or four trials rather than one — the repeating patterns become obvious across a handful of protocols in a way no single study shows.
References
- ClinicalTrials.gov, registry of clinical research studies — clinicaltrials.gov
- FDA, Drugs — regulatory framework and drug development resources — fda.gov
this page is descriptive documentation of published research design — it is not dosing guidance, a recommendation, or a protocol for use. research + education only · not medical advice. see our editorial policy.